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Objective: To investigate the diagnostic yield of contrast-enhanced computed tomography (CT) in Crohn’s disease (CD) 
patients presenting with acute severe lower gastrointestinal bleeding (LGIB), and the role of CT in predicting the risk of 
rebleeding. 
Materials and Methods: A consecutive series of 110 CD patients presenting with acute severe LGIB between 2005 and 2016 
were analyzed. Among them, 86 patients who had undergone contrast-enhanced CT constituted the study cohort. The 
diagnostic yield of CT for detecting contrast extravasation was obtained for the entire cohort and compared between 
different CT techniques. In a subgroup of 62 patients who had undergone CT enterography (CTE) and showed a negative result 
for extravasation on CTE, the association between various clinical and CTE parameters and the risk of rebleeding during 
subsequent follow-up was investigated using Cox regression analysis.
Results: The diagnostic yield of CT was 10.5% (9 of 86 patients). The yield did not significantly differ between single-
phase and multiphase examinations (p > 0.999), or between non-enterographic CT and CTE (p = 0.388). Extensive CD 
(adjusted hazard ratio [HR], 3.27; 95% confidence interval [CI], 1.09–9.80; p = 0.034) and bowel wall-to-artery 
enhancement ratio (adjusted HR, 2.81; 95% CI, 1.21–6.54; p = 0.016) were significantly independently associated with 
increased rebleeding risks, whereas anti-tumor necrosis factor-α therapy after the bleeding independently decreased the 
risk of rebleeding (adjusted HR, 0.26; 95% CI, 0.07–0.95; p = 0.041).
Conclusion: The diagnostic yield of contrast-enhanced CT was not high in CD patients presenting with acute severe LGIB. 
Nevertheless, even a negative CTE may be beneficial as it can help predict the risk of later rebleeding.
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INTRODUCTION
Acute severe lower gastrointestinal bleeding (LGIB) is an 
uncommon but potentially life-threatening complication of 
Crohn’s disease (CD), with reported incidence ranging from 
0.6% to 6% (1-8). Moreover, the risk of later rebleeding 
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is fairly high, ranging from 19% to 41% according to the 
literature (1, 2, 5, 8, 9). Diagnostic evaluation of LGIB in 
CD patients is challenging because of several factors. It 
is often difficult to determine the precise site of bleeding 
unless active bleeding is directly observed during the 
examination owing to the presence of multiple areas of 
inflammation (5, 8). When ileocolonoscopy fails to reveal 
the bleeding focus, the small bowel is difficult or even 
impossible to access with video capsule endoscopy or deep 
enteroscopy in the presence of bowel strictures (10, 11). 
Contrast-enhanced abdominopelvic computed tomography 
(CT), either routine CT or CT enterography (CTE), is generally 
recommended in patients with LGIB (11, 12). However, it 
has rarely been addressed, if the same recommendation 
applies to CD patients with LGIB, for whom the presence 
of CD poses unique difficulties to the CT evaluation. 
Unlike in other causes of LGIB, for which CT detection 
of a potential source of bleeding (such as an abnormal 
vasculature/hyperenhancement or a tumor) instead of direct 
visualization of bleeding is essentially diagnostic, a direct 
demonstration of contrast extravasation is generally needed 
for CT to determine the site of LGIB in CD. As CD patients 
typically already have multiple sites of mural abnormalities 
accompanied by hyperenhancement (a common finding of 
CD inflammation), it is impossible to know whether any 
such abnormalities are a source of bleeding unless one 
directly sees bleeding at the time of CT scan. Therefore, 
the diagnostic impact of CT might not be as apparent in 
CD patients presenting with LGIB as in patients with other 
causes of LGIB. Furthermore, as CD patients are generally 
young, radiation exposure is a concern in recommending 
a CT examination. Magnetic resonance enterography is 
currently widely used along with CT for evaluating CD 
patients (12). Although the use of magnetic resonance 
imaging to evaluate suspected small-bowel bleeding has 
been reported, supporting data are scarce; moreover, 
magnetic resonance imaging is difficult to use in emergency 
cases such as acute severe LGIB (12). In contrast, given 
that LGIB in CD patients is most likely related to CD 
itself rather than other specific causes and, therefore, its 
management often requires considering the state of CD and 
the risk of future rebleeding besides hemostatic treatment 
of the current LGIB (1, 2), performing a CT examination, 
especially using enterographic technique, might potentially 
be useful as it provides information about the state of 
CD and, furthermore, if it could suggest the risk of later 
rebleeding. Studies on the risk factors for later rebleeding 
in CD patients presenting with LGIB are scarce (1) and, to 
our knowledge, there are no related studies on the role, if 
any, of radiologic imaging.
For these reasons, it would be clinically meaningful to 
determine the diagnostic value of CT imaging specifically 
in CD patients presenting with LGIB. The purpose of this 
study was to investigate primarily the diagnostic yield 
of contrast-enhanced CT (i.e., direct CT visualization of 
bleeding) in CD patients presenting with acute severe LGIB 
and secondarily any additional role of CT in predicting the 
risk of rebleeding at later follow-up, even if not directly 
demonstrating bleeding. The knowledge would help 
guide a more appropriate evidence-based use of CT in the 
management of CD patients presenting with LGIB.
MATERIALS AND METHODS
This retrospective observational study was approved by 
the Institutional Review Board of Asan Medical Center. The 
requirement for informed consent was waived.
Patients
Crohn’s disease patients who presented with acute severe 
LGIB between January 2005 and December 2016 at Asan 
Medical Center, a tertiary academic center, were identified 
through a search of the institutional inflammatory bowel 
disease registry, by using the eligibility criteria as explained 
below. The characteristics of the registry have previously 
been detailed (13). In brief, each new patient with 
inflammatory bowel disease is registered prospectively and 
relevant data including baseline patient characteristics, 
changes in disease behavior or location, development of 
complications, usage patterns of medications, and dates and 
types of surgery are continuously updated prospectively. 
The inclusion criteria for the current study were age ≥ 18 
years and CD with acute severe LGIB. The diagnosis of CD 
was confirmed on the basis of clinical presentation and a 
combination of endoscopic, histological, radiological, and/
or biochemical criteria (14, 15). Acute severe LGIB was 
defined as profuse rectal bleeding that 1) resulted in an 
abrupt decrease in hemoglobin level to < 9 g/dL or to at 
least 2 g/dL below the baseline, or 2) required transfusion 
of at least two units of blood within 24 hours (2, 3, 5, 9). 
The exclusion criteria were postsurgical bleeding occurring 
within 30 days after surgery, to avoid including cases 
of surgery-related (instead of CD-related) bleeding and 
upper gastrointestinal (GI) bleeding as confirmed with 
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upper endoscopy. According to the eligibility criteria, 110 
consecutive patients were identified. Among them, 86 
patients (mean age ± standard deviation [SD], 35.1 ± 10.5 
years), consisting of 67 men (mean age ± SD, 34.2 ± 9.4 
years) and 19 women (mean age ± SD, 38.3 ± 10.0 years), 
underwent contrast-enhanced CT of the abdomen and pelvis 
at the time of the LGIB and were included in our study 
(Fig. 1, Table 1). All patients presented to the emergency 
department and underwent CT after achieving hemodynamic 
stability (1–12 hours after the visit).
CT Techniques
CT examinations were conducted using 16-, 32-, or 
64-slice multidetector scanners (Siemens Medical Solutions, 
Erlangen, Germany and GE Healthcare, Miwaukee, WI, USA) 
after intravenous bolus administration of 120–150 mL of 
320–370 mg I/mL contrast at a rate of 3 mL/s. Eighteen 
patients underwent non-enterographic examination (single 
portal-phase acquisition in 14 patients and dual arterial- 
and portal-phase acquisitions in 4 patients), whereas 68 
patients underwent CTE after an oral administration of 1200 
mL of 2.5% sorbitol (single enteric-phase acquisition in 28 
patients and dual arterial- and portal-phase acquisitions 
in 40 patients). CTE instead of non-enterographic CT was 
chosen whenever plausible, i.e., hemodynamic stability and 
patient’s tolerance to the oral fluid administration. The 
image acquisition parameters were as follows: beam pitch, 
1; gantry rotation time, 0.5 second; field of view to fit; 120 
kVp; and an automated tube current modulation with the 
quality reference set at 200 mAs and image reconstruction 
using standard filtered back projection for the Siemens 
scanners and a dose modulation using the noise index 
of 12.81 and image reconstruction using 30% adaptive 
statistical iterative reconstruction for the GE scanners. 
Images were reconstructed in axial and coronal planes with 
3- to 5-mm thickness with no interslice gap.
Data Collection
Clinical Data Collection
Medical records were reviewed, and the following patient- 
and disease-related characteristics were collected: age at 
presentation with acute severe LGIB (hereinafter referred to 
as index bleeding); sex; CD characteristics according to the 
Montreal classification (16), including age at CD diagnosis 
(≤ 16 years [A1], 17–40 years [A2], and > 40 years [A3]), 
disease location (ileum [L1], colon [L2], ileocolon [L3], 
and upper GI [L4]), disease behavior (non-stricturing non-
penetrating [B1], stricturing [B2], and penetrating [B3]), 
and perianal disease modifier (occurrence of perianal 
fistulae and abscesses); previous history of GI bleeding and 
bowel resection; and CD medication at the time of index 
bleeding. Use of mechanical hemostatic treatments for index 
bleeding (surgical resection, angiographic embolization, 
or endoscopic hemostasis) and use of anti-tumor necrosis 
factor (TNF)-α after index bleeding was noted. Any new 
episodes of acute severe LGIB during the follow-up after 
the index bleeding and the time (in days) until such event 
Fig. 1. Flow diagram of study patients. CD = Crohn’s disease, CT = computed tomography, LGIB = lower gastrointestinal bleeding 
110 consecutive adults (≥ 18 years) CD  
patients who presented with acute severe LGIB between 
January 2005 and December 2016
Patient who underwent CT (n = 86)
Patient who did not undergo CT (n = 24)
Negative CT results for  
bowel bleeding (n = 77)
CT examination using enterography
technique (n = 62)
Positive CT results for  
bowel bleeding (n = 9)
Pharmacotherapy  
alone (n = 3)
Endoscopic
hemostasis (n = 3)
Angiographic
embolization (n = 1)
Surgical resection 
(n = 2)
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from the CT examination for evaluating index bleeding 
were recorded. At our institution, uneventful patients were 
routinely followed up with regular visits to the outpatient 
clinic, at approximately 2-month intervals (ranging from 1 
to 3 months depending on individual patient circumstance), 
along with CD activity index measurement and laboratory 
tests. Furthermore, patients with any symptoms and 
signs requiring further medical attention could visit the 
emergency department or make additional visits to the 
outpatient clinic at any time.
CT Data Collection
Either the original clinical reading (obtained by 
experienced board-certified abdominal radiologists) or 
additional retrospective re-analysis of CT images was 
used in this study appropriately according to the analytic 
purposes. For the analysis of the diagnostic yield of CT for 
bowel bleeding, we used the original clinical CT reading to 
avoid the risk of overestimating the yield which is prone 
to occur in retrospective reassessment. A positive CT result 
was defined as contrast extravasation into the bowel lumen, 
pseudoaneurysm, or non-CD-related bowel abnormalities 
with a bleeding risk, such as neoplasms or vascular lesions. 
In addition, a board-certified experienced abdominal 
radiologist performed a retrospective rereading of the CT 
examinations without the knowledge of the findings at 
endoscopy, angiography or surgery to confirm if any positive 
findings were missed in the original clinical reading. Among 
patients whose CT showed negative results, findings of 
those who were examined using CTE (n = 62) (Fig. 1) were 
retrospectively reanalyzed to explore if any association 
existed between the CTE findings and the recurrence of 
acute severe LGIB later during the subsequent follow-up. 
We limited this image analysis to the CTE technique, as 
non-enterographic routine CT had limitations in evaluating 
CD-related bowel findings. A board-certified experienced 
abdominal radiologist, who was aware that the patients 
had CD and were examined for acute severe LGIB but was 
blinded to any other clinical data, performed a retrospective 
reanalysis of the following findings: disease extent on CTE 
categorized as non-extensive versus extensive (affecting a 
total bowel length of > 100 cm regardless of location) CD 
(17), mural thickness in millimeters, and the quantitative 
ratio between bowel wall enhancement and mesenteric 
arterial enhancement according to a method established in 
published studies (18, 19). When a dual-phase examination 
had been performed, the greater measurement was chosen 
for the analysis (19). The two latter parameters were 
obtained in the most severely affected bowel segment.
Statistical Analysis
The diagnostic yield of CT for bowel bleeding (i.e., the 
rate of direct CT visualization of bleeding evidence) was 
the primary study outcome and was determined on a per-
patient basis with its 95% confidence interval (CI). The 
diagnostic yield was compared between single- and dual-
phase examinations, as well as between non-enterographic 
CT and CTE, by using Fisher’s exact test. Secondarily, in the 
Table 1. Demographics and Clinical Characteristics of Entire 
Study Population
Variables
Entire Cohort
(n = 86)
Age at index bleeding (years)* 28.4 ± 10.0
Sex
Male 67 (77.9)
Female 19 (22.1)
Age at CD diagnosis
A1 (≤ 16 years) 8 (9.3)
A2 (17–40 years) 75 (87.2)
A3 (> 40 years) 3 (3.5)
Disease location
L1 (ileum) 46 (53.5)
L2 (colon) 1 (1.2)
L3 (ileocolon) 39 (45.3)
Disease behavior
B1 (non-stricturing non-penetrating) 64 (74.4)
B2 (stricturing) 14 (16.3)
B3 (penetrating) 8 (9.3)
Perianal disease modifier 33 (38.4)
Previous history of GI bleeding 25 (29.1)
Previous bowel resection 17 (19.8)
CD medication at time of index bleeding†
Mesalamine or sulfasalazine 49 (56.7)
Corticosteroid 11 (12.8)
Thiopurine 32 (37.2)
Infliximab 3 (3.5)
Adalimumab 1 (1.2)
Treatment for index bleeding
Surgical resection 4 (4.6)
Angiographic embolization 2 (2.4)
Endoscopic hemostasis 3 (3.5)
Pharmacotherapy alone 77 (89.5)
Anti-TNF-α therapy after index bleeding 30 (34.9)
Unless indicated otherwise, data are number of patients, with 
percentages in parentheses. *Mean ± SD, †Sum is > 86, as some 
patients were taking multiple medications. CD = Crohn’s disease, GI 
= gastrointestinal, SD = standard deviation, TNF = tumor necrosis 
factor
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subgroup of 62 patients who underwent CTE and showed 
negative results for bowel bleeding, multivariable analysis 
with Cox proportional hazard regression was performed 
to investigate the association between the CTE findings 
and the later recurrence of severe LGIB. We considered 
various clinical characteristics that might be associated 
with GI bleeding in CD patients according to published 
studies (1, 2) as covariates. Variables with p values of ≤ 
0.25 in univariable analysis were chosen as variables for 
multivariable analysis. For the multivariable analysis, a 
stepwise backward elimination method was used. Statistical 
analyses were performed using IBM SPSS Statistics for 
Windows, version 21.0 (IBM Corp., Armonk, NY, USA). A p 
value of < 0.05 was considered statistically significant.
RESULTS
Patients’ Characteristics
The detailed characteristics of the entire 86 study patients 
and subgroups of patients who underwent single- vs. dual-
phase CT and who underwent routine non-enterographic CT 
vs. CTE are presented in Tables 1 and 2.
Diagnostic Yield of CT for Bowel Bleeding
The diagnostic yield of CT for bowel bleeding was 10.5% 
(9 of 86; 95% CI, 5.4–18.9%) using the clinical definition 
of acute severe LGIB mentioned previously as the reference 
standard, according to the original clinical reading. 
There was no additional detection of bowel bleeding at 
the retrospective reanalysis of the images compared to 
the original clinical reading. All positive CT results were 
demonstrations of active contrast extravasation, all in areas 
of active CD inflammation (Fig. 2), including the jejunum 
(n = 1), ileum (n = 6), and cecum (n = 2), and there were 
no cases of CT detection of non-CD-related bowel lesions 
to indicate potential sources of bleeding. The yield was 
not significantly different between single-phase (9.5%, 
4 of 42) and dual-phase (11.4%, 5 of 44) CT studies (p 
> 0.999). In all five patients examined with dual-phase 
CT, contrast extravasation was clearly recognized at both 
arterial and portal phases. The different yields between 
non-enterographic CT (16.7%, 3 of 18) and CTE (8.8%, 6 of 
68) shown in the study sample did not reach a statistical 
significance (p = 0.388).
Of the nine patients who had positive results for active 
bleeding on CT, two patients received surgery, one patient 
Table 2. Patient Characteristics in Select Subgroups
Variables
Single- vs. Dual-Phase CT Routine vs. Enterographic CT
Single-Phase CT 
(n = 42)
Dual-Phase CT 
(n = 44)
P
Non-CTE
(n = 18)
CTE
(n = 68)
P
Age at index bleeding (years)* 29.3 ± 11.7 27.5 ± 8.2 0.410 27.9 ± 13.5 28.5 ± 9.0 0.871
Sex 0.441 0.532
Male 31 (73.8) 36 (81.8) 13 (72.2) 54 (79.4)
Female 11 (26.2) 8 (18.2) 5 (27.8) 14 (20.6)
Age at CD diagnosis 0.888 > 0.999
A1 (≤ 16 years) 4 (9.5) 4 (9.1) 2 (11.1) 6 (8.8)
A2 (17–40 years) 36 (85.7) 39 (88.6) 15 (83.3) 60 (88.2)
A3 (> 40 years) 2 (4.8) 1 (2.3) 1 (5.6) 2 (2.9)
Disease location > 0.999 0.548
L1 (ileum) 23 (54.8) 23 (52.3) 8 (44.4) 38 (55.9)
L2 (colon) 0 (0) 1 (2.3) 0 (0) 1 (1.5)
L3 (ileocolon) 19 (45.2) 20 (45.5) 10 (55.6) 29 (42.6)
Disease behavior 0.039 0.121
B1 (non-stricturing non-penetrating) 27 (64.3) 37 (84.1) 11 (61.1) 53 (77.9)
B2 (stricturing) 8 (19.0) 6 (13.6) 3 (16.7) 11 (16.2)
B3 (penetrating) 7 (16.7) 1 (2.3) 4 (22.2) 4 (5.9)
Perianal disease modifier 17 (40.5) 16 (36.4) 0.825 7 (38.9) 26 (38.2) > 0.999
Previous history of gastrointestinal bleeding 14 (33.3) 11 (25.0) 0.479 4 (22.2) 21 (30.9) 0.569
Previous bowel resection 6 (14.3) 11 (25.0) 0.281 2 (11.1) 15 (22.1) 0.349
Unless indicated otherwise, data are number of patients, with percentages in parentheses. *Mean ± SD. CT = computed tomography, CTE = 
CT enterography
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(of two patients who underwent angiography) received 
angiographic embolization, three patients received 
endoscopic hemostasis, and three patients received 
pharmacotherapy alone. LGIB was successfully resolved by 
treating the extravasation seen on CT in all patients. Among 
the 77 patients with negative CT results for bowel bleeding, 
two patients received surgery, one patient (out of eight 
patients who underwent angiography) received angiographic 
embolization as angiography successfully revealed a 
bleeding focus, and two patients received endoscopic 
hemostasis after endoscopic confirmation of bleeding.
Prediction of Future Rebleeding in Patients with 
Negative CTE Findings
In the subgroup of 62 patients who underwent CTE and 
showed negative results for bowel bleeding on CTE, severe 
LGIB recurred in 20 patients (32.3%) during the follow-up 
(median, 73.3 months; range, 12.7–133.6 months), 2.4–85.6 
months after the index bleeding (median, 30.0 months). 
The cumulative rates of recurred severe LGIB at 1, 3, and 5 
years were 4.8%, 22.7%, and 36.6%, respectively (Fig. 3A). 
The results of Cox proportional hazard regression to identify 
risk factors associated with recurrence of severe LGIB are 
presented in Table 3. According to the multivariable analysis 
accounting for variables listed in Table 3, when the bowel 
wall-to-artery enhancement ratio was included as ordinal 
data grouped in terciles, extensive CD as assessed with CTE 
(adjusted hazard ratio [HR], 3.27; 95% CI, 1.09–9.80; p = 
0.034) and greater bowel wall-to-artery enhancement ratio 
(adjusted HR, 2.81; 95% CI, 1.21–6.54; p = 0.016) were 
significantly independently associated with increased risks 
of rebleeding, whereas treatment with anti-TNF-α therapy 
after the index bleeding independently decreased the risk 
of rebleeding (adjusted HR, 0.26; 95% CI, 0.07–0.95; p 
= 0.041) (Table 3, Fig. 3B-D). The results were largely 
consistent when the bowel wall-to-artery enhancement 
ratio was considered as continuous data despite somewhat 
unstable model estimation (Table 3).
DISCUSSION
In this study, the overall diagnostic yield of contrast-
enhanced CT in CD patients presenting with acute severe 
LGIB was not very high (10.5%, 9 of 86). Nevertheless, 
even if CT did not reveal the origin of bleeding specifically, 
a CT examination performed as enterography was still 
useful as it could help predict the risk of future recurrence 
of severe LGIB. The diagnostic yield of CT in this study 
was apparently lower than those reported in more general 
settings (essentially non-CD) of LGIB. According to one 
review, the overall diagnostic yield of CT in LGIB patients 
consisting of mostly non-CD patients was 60%, with the 
lowest report of 25% (20). Furthermore, several studies 
reported CTE yields of 24.1% to 26.6% in patients suspected 
of having small-bowel bleeding (21-23). The lower yield of 
CT in our study is likely related to several factors. First, a 
direct demonstration of contrast extravasation (instead of 
bowel abnormalities that can bleed, if not already bleeding 
Fig. 2. 20-year-old male patient with CD presenting with acute severe LGIB. 
Axial (A) and coronal (B) CTE images show contrast extravasation into bowel lumen (arrows), indicating ongoing bleeding in ileal area that 
shows mural thickening and hyperenhancement, ulcers, and increased vasa recta, which are signs of active Crohn’s inflammation. CTE = CT 
enterography
BA
1095
CT in Crohn’s Disease with Lower GI Bleeding
Korean J Radiol 19(6), Nov/Dec 2018kjronline.org
at the time of examination) was needed to make a positive 
call of GI bleeding on CT because of the pre-existing 
hyperenhancing mural lesions in CD. Second, as patients 
were examined after achieving hemodynamic stability, many 
patients might have been in temporary hemostasis state. 
Third, oral fluid administration used with CTE might have 
diluted small amounts of extravasated contrast material, 
thereby decreasing the ability to detect subtle active 
bleeding. Although the diagnostic yields for LGIB were not 
significantly different between CTE and non-enterographic 
CT in this study, the point estimate value was smaller for 
CTE (8.8% compared with 16.7% for non-enterographic CT). 
Further confirmation in a larger study would be worthwhile, 
as this statistical comparison is likely limited owing to 
the retrospective nature and the small number of patients 
who underwent non-enterographic CT. Additionally, the 
low yield may be due to the nature of CD itself, as the 
previous studies seldom included CD patients. Although the 
diagnostic yield of CT was low in this study, the localization 
of bleeding by CT, when achieved, was effective in that 
Fig. 3. Cumulative probability of recurred severe LGIB in 62 patients who were examined with CTE and showed negative CTE 
results for bowel bleeding. 
Overall result (A) and results according to disease extent assessed with CTE (B), bowel-to-artery enhancement ratio assessed with CTE (C), and 
anti-TNF-α therapy after index bleeding (D). CI = confidence interval, HR = hazard ratio, TNF = tumor necrosis factor
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LGIB could successfully be resolved by treating the bleeding 
identified on CT in all patients.
For evaluating GI bleeding, multiphase CT including 
unenhanced, arterial, and portal phases is generally 
recommended (12, 24). Unenhanced images are helpful 
in differentiating active bleeding from any preexisting 
intraluminal hyperattenuating pseudolesions. For contrast-
enhanced images, combining findings from arterial and 
Table 3. Univariable and Multivariable Cox Analyses of Risk Factors for Recurrence of Severe LGIB (for 62 Patients Who Underwent 
CTE and Showed Negative Results for Bowel Bleeding)
Variables n
 Univariable Analysis Multivariable AnalysisⅡ Multivariable Analysis¶
HR (95% CI) P
Adjusted HR
(95% CI)
P
Adjusted HR
(95% CI)
P
Age at index bleeding* 1.00 (0.96–1.05) 0.886
Sex
Male 49 1 (Reference) –
Female 13 0.07 (0.20–2.35) 0.548
Age at CD diagnosis* 0.99 (0.94–1.04) 0.726
Colon involvement Stepwise eliminated Stepwise eliminated
No 37 1 (Reference) –
Yes 25 0.57 (0.22–1.49) 0.25
Montreal behavior
B1 (non-stricturing non-penetrating) 48 1 (Reference) –
B2 or B3 (stricturing or penetrating) 14 0.34 (0.08–1.45) 0.336
Perianal disease modifier Stepwise eliminated Stepwise eliminated
No 39 1 (Reference) –
Yes 23 0.51 (0.18–1.40) 0.189
Previous history of GI bleeding 
No 42 1 (Reference) –
Yes 20 1.48 (0.60–3.63) 0.39
Previous bowel resection
No 48 1 (Reference) –
Yes 14 1.63 (0.59–4.51) 0.346
Thiopurine use at time of index bleeding
No 37 1 (Reference) –
Yes 25 1.34 (0.56–3.24) 0.512
Mechanical hemostasis for index bleeding†
No 59 1 (Reference)
Yes 3 1.27 (0.17–9.54) 0.816
Anti-TNF-α therapy after index bleeding
No 40 1 (Reference) – 1 (Reference) – 1 (Reference) –
Yes 22 0.21 (0.06–0.73) 0.014 0.26 (0.07–0.95) 0.041 0.29 (0.08–1.07) 0.063
Disease extent (assessed on CTE)
Non-extensive CD 51 1 (Reference) – 1 (Reference) – 1 (Reference) –
Extensive CD 11 8.37 (3.03–23.11) < 0.001 3.27 (1.09–9.80) 0.034 3.07 (1.03–9.20) 0.045
Mural thickness (assessed on CTE)‡ 1.36 (1.12–1.65) 0.002 Stepwise eliminated Stepwise eliminated
Bowel wall-to-artery enhancement ratio (assessed on CTE)
As ordinal categories grouped in  
  terciles (≤ 0.5, > 0.5 and ≤ 0.7, > 0.7)
3.33 (1.54–7.22) 0.002 2.81 (1.21–6.54) 0.016 N/A N/A
As continuous data§
1284.15 
(21.54–76547.38)
0.001 N/A N/A
201.76 
(3.35–12137.95)
0.011
*HR per 1 year increase, †Surgery (n = 2) and angiographic embolization (n = 1), ‡HR per 1-mm increase, §HR per 0.1 increase of index 
value, ⅡMultivariable Cox proportional hazard regression including bowel-to-artery enhancement ratio as ordinal data (grouped in 
terciles) for more stable statistical modeling given moderate sample size, ¶Multivariable Cox proportional hazard regression including 
bowel-to-artery enhancement ratio as continuous data. CI = confidence interval, HR = hazard ratio, LGIB = lower gastrointestinal 
bleeding, N/A = not applicable
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portal phases may reveal increase in size and change in 
morphology of the extravasated contrast with time, which 
may help recognize active bleeding. By contrast, our 
study results do not indicate that the diagnostic yield of 
multiphase CT is superior to single-phase CT for detecting 
bleeding. Although, in all five CD patients examined with 
multiphase CT, contrast extravasation was clearly depicted 
at both arterial and portal phases, all of our study patients 
had severe bleeding and the difference of multiphase 
versus single-phase scans may likely be more pronounced 
in patients with less severe bleeding. Considering these 
results and the low diagnostic yield of CT, routine use of 
multiphase CT in CD patients presenting with acute severe 
LGIB may probably be excessive and such an approach may 
cause unbeneficial radiation exposure to many patients, 
which could be a concern considering that CD patients 
are mostly young and are subject to multiple repeated 
radiologic examinations. However, these results are limited 
due to the retrospective comparison and the modest sample 
size, although the patient characteristics were grossly 
similar between the two techniques. Further confirmation 
would be needed.
Both non-enterographic routine CT and CTE can be used 
to evaluate LGIB depending on patient circumstance (12). 
The oral administration of neutral fluid contrast used for CTE 
substantially increases the detection of bowel abnormalities 
per se compared with non-enterographic CT. However, as 
mentioned earlier, the fluid may dilute extravasated contrast 
material, thereby decreasing the ability to detect subtle 
active bleeding. Therefore, CTE could be disadvantageous 
in a situation where direct visualization of contrast 
extravasation is needed, like CD patients presenting with 
bleeding. One potential advantage of performing CTE in CD 
patients presenting with acute severe LGIB is obtaining 
information to predict the risk of future rebleeding. 
Considering that acute severe LGIB is a potentially life-
threatening complication and that recurrence is not rare in 
CD patients, estimating the risk of future rebleeding would 
be important. Our study is seemingly the first study to 
explore CTE findings as predictors of occurrence of future 
rebleeding in CD patients presenting with acute severe 
LGIB. Both extensive CD as assessed with CTE and greater 
bowel wall-to-artery enhancement ratio were independent 
predictors for the risk of rebleeding. The etiology of severe 
LGIB in CD patients has not been fully elucidated; however, 
one possible explanation is a transmural inflammation 
leading to the penetration and erosion of large vessels 
(25). The association between the CTE findings and the 
risk of rebleeding seems compatible with this theory, as 
the CTE findings reflect more extensive and more severe 
inflammation. The advantages and disadvantages of CTE vs. 
non-enterographic CT for CD patients presenting with acute 
severe LGIB should be clarified further with more studies to 
determine the optimal scan techniques for these patients.
Use of anti-TNF-α therapy after the index bleeding 
was independently negatively associated with the risk of 
rebleeding in our study. Similarly, there have been reports 
of the beneficial effects of anti-TNF-α in CD patients 
presenting with acute severe LGIB (26-33). Anti-TNF-α 
agents have been shown to induce and maintain mucosal 
healing (34); thereby, these may treat the bleeding and 
prevent recurrent bleeding. Our study is also meaningful in 
that it provides further proof for anti-TNF-α as a therapy for 
LGIB in CD.
Our study has several limitations. First, it was a 
retrospective study of modest sample size; therefore, it is 
prone to potential selection bias. Not all eligible patients 
underwent CT, and the analysis of CT findings concerning 
the risk of rebleeding only applies to those who underwent 
CTE. Second, our results were from a single-center 
experience. Therefore, further prospective confirmation of 
the results in a multicenter setting that includes a larger 
number of patients would be needed.
In conclusion, the diagnostic yield of contrast-enhanced 
CT was not high in CD patients presenting with acute severe 
LGIB. Nevertheless, even a negative CTE may likely be 
beneficial, as it can help predict the risk of later rebleeding. 
Further studies are needed to determine the optimal CT 
techniques for these patients.
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